A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 341 participants.
Also called NCT02277691
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 341 participants
- Sponsor
- Registry
-
NCT02277691 -
U1111-1163-0169
-
- Other papers using this trial's data
- A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02277691. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11-07 (actual); primary completion 2016-04-25 (actual). Results posted on 2017-06-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- TAK-536TCH tablet
- Intervention (Drug)
- TAK-536CCB tablet
- Intervention (Drug)
- HCTZ 12.5 mg tablet
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02277691- Content hash
2f2af60633503a4a2289b46ba37bca0b6d1397c2172b231a3a114d3d5cfbcf13